• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Document › Details

PharmaMar S.A.. (1/18/18). "Press Release: Pharma Mar, S.A. Announces the Results of the Phase III Clinical Trial (CORAIL) with Zepsyre (lurbinectedin) in Platinum-resistant Ovarian Cancer patients". Colmenar Viejo (Madrid).

	Organisation	PharmaMar S.A. (MSE: PHM)
	Group	PharmaMar (Group)
	Product	Zepsyre®
	Product 2	clinical research

Pursuant to article 228 of the consolidated text of the Spanish Securities Market Act, we hereby inform you of the following SIGNIFICANT EVENT:


“Pharma Mar, S.A. announces the results of the Phase III clinical trial (CORAIL) with Zepsyre® (lurbinectedin) in platinum-resistant ovarian cancer patients.

The CORAIL trial, comparing Zepsyre® versus topotecan or PLD (liposomal doxorubicin) in platinum resistant ovarian cancer patients has not met the primary end-point of the trial, which was PFS (Progression Free Survival).

The antitumoral activity of the three compounds Zepsyre®, topotecan and PLD, in terms of PFS, has been the same. In the CORAIL trial Zepsyre® has demonstrated a better safety profile than the control arm.

Results of this trial will be presented at future oncology congresses.”


Pharma Mar S.A. Avda. de los Reyes, 1 P.I. La Mina 28770 Colmenar Viejo (Madrid) Spain Ph.: +34 91 846 6000 Fax.: +34 91 846 6001 www.pharmamar.com

Record changed: 2018-01-25

Advertisement

More documents for PharmaMar (Group)

• [1] PharmaMar S.A.. (2/14/18). "Press Release: PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates". Madrid....
• [2] Genomica SAU. (1/18/18). "Press Release: Genomica Opens Its First Subsidiary in China". Madrid....
• [3] PharmaMar S.A.. (5/18/17). "Press Release: PharmaMar Announces New Data with Its Compounds Yondelis and Lurbinectedin during ASCO 2017". Madrid....
• [4] PharmaMar S.A.. (5/17/17). "Press Release: PharmaMar and Specialised Therapeutics Asia Sign Licensing and Marketing Agreement for Lurbinectedin Covering Australia, New Zealand and Several Asian Countries". Madrid....
• [5] PharmaMar S.A.. (5/4/17). "Press Release: Aplidin Receives Orphan Drug Status for the Treatment of Multiple Myeloma in Switzerland". Madrid....
• [6] PharmaMar S.A.. (12/1/16). "Press Release: PharmaMar Presents Positive Results with Its Conjugated Antibody MI130110 in CD13-expressing Tumor-cells". Madrid....
• [7] PharmaMar S.A.. (11/28/16). "Press Release: PharmaMar Begins a Phase I Study of PM1183 in Japan for the Treatment of Solid Tumors". Madrid....
• [8] PharmaMar S.A.. (11/16/16). "Press Release: PharmaMar Appoints Pascal Besman as Chief Operating Officer of PharmaMar U.S.". Madrid & New York, NY....
• [9] PharmaMar S.A.. (11/10/16). "Press Release: PharmaMar Shows New Clinical Data with Yondelis in Different Sarcoma Subtypes at CTOS 2016". Madrid....
• [10] PharmaMar S.A.. (10/28/16). "Press Release: The EMA Accepts to Assess the Marketing Authorization Application from PharmaMar for Aplidin". Madrid....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2018. Made in Germany.